{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:45:55Z","timestamp":1786427155507,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-025-01277-w","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T06:27:49Z","timestamp":1755930469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Simulating tumor complexity: 3D pancreatic tumor spheroid model for improved drug screening"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6997-7528","authenticated-orcid":false,"given":"Bano","family":"Subia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarup","family":"Ghoshdastidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasinath","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"1277_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2023.1201419","author":"N Singh","year":"2023","unstructured":"Singh N, Vayer P, Tanwar S, Poyet J-L, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Front Drug Discov. 2023. https:\/\/doi.org\/10.3389\/fddsv.2023.1201419.","journal-title":"Front Drug Discov"},{"issue":"7","key":"1277_CR2","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B. 2022;12(7):3049\u201362. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.002.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"7","key":"1277_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacbts.2019.10.008","volume":"4","author":"GA Van Norman","year":"2019","unstructured":"Van Norman GA. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl Sci. 2019;4(7):845\u201354. https:\/\/doi.org\/10.1016\/j.jacbts.2019.10.008.","journal-title":"JACC Basic Transl Sci"},{"key":"1277_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12: 656364. https:\/\/doi.org\/10.3389\/fimmu.2021.656364.","journal-title":"Front Immunol"},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fmolb.2020.00033","volume":"7","author":"C Jensen","year":"2020","unstructured":"Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci. 2020;7:33. https:\/\/doi.org\/10.3389\/fmolb.2020.00033.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"1277_CR6","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1021\/am506094c","volume":"7","author":"B Subia","year":"2015","unstructured":"Subia B, Dey T, Sharma S, Kundu SC. Target specific delivery of anticancer drug in silk fibroin based 3D distribution model of bone-breast cancer cells. ACS Appl Mater Interfaces. 2015;7(4):2269\u201379. https:\/\/doi.org\/10.1021\/am506094c.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"1277_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080926","volume":"15","author":"SM Badr-Eldin","year":"2022","unstructured":"Badr-Eldin SM, Aldawsari HM, Kotta S, Deb PK, Venugopala KN. Three-dimensional in vitro cell culture models for efficient drug discovery: progress so far and future prospects. Pharmaceuticals. 2022;15(8): 926. https:\/\/doi.org\/10.3390\/ph15080926.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1277_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/cancers14010190","volume":"14","author":"MAG Barbosa","year":"2021","unstructured":"Barbosa MAG, Xavier CPR, Pereira RF, Petrikait\u0117 V, Vasconcelos MH. 3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs. Cancers. 2021;14(1):190. https:\/\/doi.org\/10.3390\/cancers14010190.","journal-title":"Cancers"},{"issue":"12","key":"1277_CR9","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.3390\/cancers13122970","volume":"13","author":"F Fontana","year":"2021","unstructured":"Fontana F, Marzagalli M, Sommariva M, Gagliano N, Limonta P. In vitro 3D cultures to model the tumor microenvironment. Cancers. 2021;13(12):2970. https:\/\/doi.org\/10.3390\/cancers13122970.","journal-title":"Cancers"},{"key":"1277_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123184","volume":"358","author":"T Patel","year":"2024","unstructured":"Patel T, Jain N. Multicellular tumor spheroids: a convenient in vitro model for translational cancer research. Life Sci. 2024;358: 123184. https:\/\/doi.org\/10.1016\/j.lfs.2024.123184.","journal-title":"Life Sci"},{"issue":"4","key":"1277_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","volume":"30","author":"D Wei","year":"2024","unstructured":"Wei D, Wang L, Zuo X, Maitra A, Bresalier RS. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res. 2024;30(4):655\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2098.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 3","key":"1277_CR12","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.4103\/eus.eus_60_17","volume":"6","author":"NLH Bekkali","year":"2017","unstructured":"Bekkali NLH, Oppong KW. Pancreatic ductal adenocarcinoma epidemiology and risk assessment: could we prevent? Possibility for an early diagnosis. Endosc Ultrasound. 2017;6(Suppl 3):S58\u201361. https:\/\/doi.org\/10.4103\/eus.eus_60_17.","journal-title":"Endosc Ultrasound"},{"issue":"9","key":"1277_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340. https:\/\/doi.org\/10.1038\/s41571-020-0363-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"1277_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2020.12.057","volume":"331","author":"B Subia","year":"2021","unstructured":"Subia B, Dahiya UR, Mishra S, Ayache J, Casquillas GV, Caballero D, Reis RL, Kundu SC. Breast tumor-on-chip models: from disease modeling to personalized drug screening. J Control Release. 2021;331:103\u201320. https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.057.","journal-title":"J Control Release"},{"issue":"9","key":"1277_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, Liu L, Huang D, Jiang J, Cui GS, Yang Y, Wang W, Guo D, Dai M, Guo J, Zhang T, Liao Q, Liu Y, Zhao YL, Han DL, Zhao Y, Yang Y-G, Wu W. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):725\u201338. https:\/\/doi.org\/10.1038\/s41422-019-0195-y.","journal-title":"Cell Res"},{"key":"1277_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.actbio.2018.08.008","volume":"78","author":"G Lazzari","year":"2018","unstructured":"Lazzari G, Nicolas V, Matsusaki M, Akashi M, Couvreur P, Mura S. Multicellular spheroid based on a triple co-culture: a novel 3D model to mimic pancreatic tumor complexity. Acta Biomater. 2018;78:296\u2013307. https:\/\/doi.org\/10.1016\/j.actbio.2018.08.008.","journal-title":"Acta Biomater"},{"issue":"1","key":"1277_CR17","doi-asserted-by":"publisher","DOI":"10.1063\/5.0242490","volume":"9","author":"SC Hern\u00e1ndez-HatibiBorau","year":"2025","unstructured":"Hern\u00e1ndez-HatibiBorau SC, Mart\u00ednez-BoschNavarro NP, Garc\u00eda-Aznar JM, Guerrero PE. Quantitative characterization of the 3D self-organization of PDAC tumor spheroids reveals cell type and matrix dependence through advanced microscopy analysis. APL Bioeng. 2025;9(1): 016116. https:\/\/doi.org\/10.1063\/5.0242490.","journal-title":"APL Bioeng"},{"issue":"1","key":"1277_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07110-x","volume":"20","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Feeney K, Lee MA, Mu\u00f1oz A, Graci\u00e1n AC, Lonardi S, Ryoo BY, Hung A, Lin Y, Bendell J, Hecht JR. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer. 2020;20(1): 633. https:\/\/doi.org\/10.1186\/s12885-020-07110-x.","journal-title":"BMC Cancer"},{"issue":"9","key":"1277_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O\u2019Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0349.","journal-title":"Cancer Discov"},{"issue":"10","key":"1277_CR20","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Christensen JG. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28(10):2171\u201382. https:\/\/doi.org\/10.1038\/s41591-022-02007-7.","journal-title":"Nat Med"},{"key":"1277_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611948","volume":"30","author":"E Moln\u00e1r","year":"2024","unstructured":"Moln\u00e1r E, Baranyi M, Szigeti K, Heged\u0171s L, Bord\u00e1s F, G\u00e1briel Z, Pet\u00e9nyi G, T\u00f3v\u00e1ri J, Heged\u0171s B, T\u00edm\u00e1r J. Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer. Pathol Oncol Res. 2024;30: 1611948. https:\/\/doi.org\/10.3389\/pore.2024.1611948.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"1277_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12935-021-01853-8","volume":"21","author":"SJ Han","year":"2021","unstructured":"Han SJ, Kwon S, Kim KS. Challenges of applying multicellular tumor spheroids in preclinical phase. Cancer Cell Int. 2021;21(1):152. https:\/\/doi.org\/10.1186\/s12935-021-01853-8.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"1277_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.yexcr.2018.12.013","volume":"374","author":"T Annese","year":"2019","unstructured":"Annese T, Tamma R, Ruggieri S, Ribatti D. Erythropoietin in tumor angiogenesis. Exp Cell Res. 2019;374(2):266\u201373. https:\/\/doi.org\/10.1016\/j.yexcr.2018.12.013.","journal-title":"Exp Cell Res"},{"key":"1277_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.semcancer.2024.09.002","volume":"106","author":"G Lencioni","year":"2024","unstructured":"Lencioni G, Gregori A, Toledo B, Rebelo R, Immordino B, Amrutkar M, Xavier CPR, Kocijan\u010di\u010d A, Pandey DP, Per\u00e1n M, Casta\u00f1o JP, Walsh N, Giovannetti E. Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems. Semin Cancer Biol. 2024;106:217\u201333. https:\/\/doi.org\/10.1016\/j.semcancer.2024.09.002.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1277_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/cancers11030381","volume":"11","author":"T Annese","year":"2019","unstructured":"Annese T, Tamma R, Ruggieri S, Ribatti D. Angiogenesis in pancreatic cancer: pre-clinical and clinical studies. Cancers. 2019;11(3):381. https:\/\/doi.org\/10.3390\/cancers11030381.","journal-title":"Cancers"},{"key":"1277_CR26","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.71923","author":"\u00d6S Aslant\u00fcrk","year":"2018","unstructured":"Aslant\u00fcrk \u00d6S. In vitro cytotoxicity and cell viability assays: principles, advantages, and disadvantages. Genotoxicity Predict Risk Actual World. 2018. https:\/\/doi.org\/10.5772\/intechopen.71923.","journal-title":"Genotoxicity Predict Risk Actual World"},{"issue":"2","key":"1277_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101966","volume":"6","author":"X Jiang","year":"2025","unstructured":"Jiang X, Wang T, Zhao B, Sun H, Dong Y, Ma Y, Li Z, Wu Y, Wang K, Guan X, Long B, Qin L, Shi W, Shi L, He Q, Liu W, Li M, Xiao L, Zhou C, Sun H, Yang J, Guan J, Zhou H, Yu Z, Jiao Z. KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Cell Rep Med. 2025;6(2): 101966. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101966.","journal-title":"Cell Rep Med"},{"issue":"7","key":"1277_CR28","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/0008-5472.CAN-23-2504","volume":"84","author":"V Kumarasamy","year":"2024","unstructured":"Kumarasamy V, Wang J, Frangou C, Wan Y, Dynka A, Rosenheck H, Dey P, Abel EV, Knudsen ES, Witkiewicz AK. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 2024;84(7):1115\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2504.","journal-title":"Cancer Res"},{"key":"1277_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-95","author":"P Longati","year":"2013","unstructured":"Longati P, Jia X, Eimer J, Wagman A, Witt M, Rehnmark S, Verbeke C, Toftg\u00e5rd R, L\u00f6hr M, Heuchel RL. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer. 2013. https:\/\/doi.org\/10.1186\/1471-2407-13-95.","journal-title":"BMC Cancer"},{"issue":"11","key":"1277_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188100","volume":"12","author":"A Virgone-Carlotta","year":"2017","unstructured":"Virgone-Carlotta A, Lemasson M, Mertani HC, Diaz J, Monnier S, Dehoux T, Delano\u00eb-Ayari H, Rivi\u00e8re C, Rieu J. In-depth phenotypic characterization of multicellular tumor spheroids: effects of 5-fluorouracil. PLoS ONE. 2017;12(11): e0188100. https:\/\/doi.org\/10.1371\/journal.pone.0188100.","journal-title":"PLoS ONE"},{"issue":"6","key":"1277_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/cells14060450","volume":"14","author":"R Verloy","year":"2025","unstructured":"Verloy R, Privat-Maldonado A, Van Audenaerde J, Rovers S, Zaryouh H, De Waele J, Quatannens D, Peeters D, Roeyen G, Deben C, Smits E, Bogaerts A. Capturing the heterogeneity of the PDAC tumor microenvironment: novel triple co-culture spheroids for drug screening and angiogenic evaluation. Cells. 2025;14(6):450. https:\/\/doi.org\/10.3390\/cells14060450.","journal-title":"Cells"},{"issue":"8","key":"1277_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/cancers9080098","volume":"9","author":"E Forte","year":"2017","unstructured":"Forte E, Chimenti I, Rosa P, Angelini F, Pagano F, Calogero A, Giacomello A, Messina E. EMT\/MET at the crossroad of stemness, regeneration and oncogenesis: the ying-yang equilibrium recapitulated in cell spheroids. Cancers. 2017;9(8):98. https:\/\/doi.org\/10.3390\/cancers9080098.","journal-title":"Cancers"},{"issue":"1","key":"1277_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92. https:\/\/doi.org\/10.1038\/s41392-024-01808-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1277_CR34","first-page":"6724","volume":"8","author":"XP Li","year":"2015","unstructured":"Li XP, Zhang XW, Zheng LZ, Guo WJ. Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol. 2015;8(6):6724\u201331.","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"1277_CR35","doi-asserted-by":"publisher","first-page":"888","DOI":"10.14348\/molcells.2014.0207","volume":"37","author":"Y Kim","year":"2014","unstructured":"Kim Y, Han D, Min H, Jin J, Yi EC, Kim Y. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines. Mol Cells. 2014;37(12):888\u201398. https:\/\/doi.org\/10.14348\/molcells.2014.0207.","journal-title":"Mol Cells"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01277-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:27:48Z","timestamp":1757147268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01277-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01277-w","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest associated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"149"}}